Raising the lower end of the revenue forecast indicates Xeris Biopharma's confidence in its financial performance and operational efficiency. This positive adjustment, although minor, could instill investor confidence and potentially lead to a short-term uptick in the stock price, as it aligns closely with analyst expectations.